据悉，第八届进博会将于2025年11月5日至10日在国家会展中心（上海）举办，继续由国家综合 展、企业商业展、虹桥国际经济论坛、配套活动和人文交流活动等组成。企业商业展设立医疗器械及医 药保健（健康中国，美好生活）、汽车及智慧出行（出行，无限可能）、技术装备（创新与可持续未 来）、消费品（更高品质，更好生活）、农食产品（从全球农场到中国餐桌）、服务贸易（数字、互 联、绿色）六大展区及创新孵化专区（在中国，切入新赛道），将进一步创新展览题材，丰富展览内 容，更加聚焦全球领先的新产品、新技术、新服务，加大力度挖掘关键核心技术和产品。同时，还将继 续举办贸易投资对接会、重要采购商选品会、采购商"长廊"等展期活动，多维度打造展客商双向对接平 台，促进展客商深度交流与合作。 参展方面，国家综合展招展工作已全面启动，广泛邀请有意愿的国家和国际组织参展，展示综合形 象、贸易投资机遇、特色产业和优势产品等。企业商业展方面，已有来自70多个国家近800家企业签 约，展览面积近25万平方米。首批300余家参展商名单正式公布，其中，超100家展商为自首届进博会举 办以来连续8届参展的"全勤生"，充分体现各方对中国经济和进博会的信心 ...

Core Viewpoint - Sanofi is showcasing its innovative products at the 2025 China Beijing International Science and Technology Industry Expo, emphasizing its commitment to advancing immunology and local healthcare integration in China [1][2] Group 1: Company Strategy - China is Sanofi's second-largest market, and the company is accelerating the introduction of over 60 innovative drugs and vaccines in the country [1][2] - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, contributing to over 90% of its global R&D projects [2] Group 2: Collaboration and Partnerships - Sanofi collaborates with local biopharmaceutical companies like Jixing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [2] - The company has formed a specialized pharmaceutical innovation fund with KKR to expedite the commercialization of local research outcomes [2] Group 3: Production and Supply Chain - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [2] - The Beijing production base in Yizhuang is the largest insulin injection production facility for Sanofi in the Asia-Pacific region [2]

Group 1 - The 2025 Beijing International Technology Industry Expo focuses on strategic emerging industries, particularly biomedicine, showcasing the achievements of Beijing's international technology innovation center [1] - Sanofi highlights its commitment to immunology innovation and local scientific ecosystem development, presenting nine breakthrough therapies across key disease areas [1] - Sanofi has introduced over 60 innovative drugs and vaccines to China, addressing seven of the top ten deadly diseases in the country [1] Group 2 - China is Sanofi's second-largest market, with over 90% of its global R&D projects involving Chinese participation, establishing China as a critical component of Sanofi's global R&D strategy [2] - Sanofi collaborates with leading local biopharmaceutical companies to accelerate the development of cutting-edge therapies in oncology and immunology [2] - The company has established a special pharmaceutical innovation fund in partnership with KKR to facilitate the commercialization of local research achievements [2] Group 3 - In December 2024, Sanofi announced a €1 billion investment to build an insulin production facility in Beijing, marking the largest single investment by the company in China [3] - Sanofi has developed a large-scale local production and supply network covering key regions in China, including Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Greater Bay Area [3] - The company aims to strengthen its integrated industrial chain from R&D to production and operations in China, enhancing local healthcare development [3]

Core Viewpoint - Sanofi showcased its global innovative products at the 2025 Beijing International Technology Industry Expo, emphasizing its commitment to the Chinese market and its role in advancing the local biopharmaceutical ecosystem [1][3]. Group 1: Company Strategy and Market Position - Sanofi focuses on immunology innovation, presenting nine breakthrough therapies addressing key disease areas such as respiratory diseases, skin immunity, and metabolic diseases [3]. - The company has introduced over 60 innovative drugs and vaccines to China, covering seven of the top ten deadliest diseases in the country, thereby addressing unmet medical needs [3]. - China is Sanofi's second-largest market, and the company aims to leverage global resources to enhance local practices and accelerate the translation of pharmaceutical innovations [3]. Group 2: Research and Development - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, creating a nationwide research network [3]. - Over 90% of Sanofi's global R&D projects involve China, highlighting the country's significant role in the company's innovation capabilities [3]. Group 3: Local Partnerships and Collaborations - Sanofi collaborates with leading local biopharmaceutical companies such as Jinxing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [3]. - The company has formed a specialized pharmaceutical innovation fund with KKR to accelerate the commercialization of local research outcomes [3]. - Sanofi actively explores innovative business models with industry partners like Shanghai Pharmaceuticals to improve accessibility to primary healthcare services [3]. Group 4: Manufacturing and Investment - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [4]. - The Beijing production base, designed to international standards, is the largest insulin injection production facility in the Asia-Pacific region [4]. - In December 2024, Sanofi announced a €1 billion investment to establish a new insulin production base in Beijing, marking the company's largest single investment in China [4].